NYXH Stock Analysis: “Up 29%, Guided Down” — Ramp Problem or Runway Problem?

Nyxoah (NASDAQ: NYXH) released preliminary third-quarter numbers at 8:00 Monday morning, October 19, and managed to announce an acceleration and a guidance cut in the same page. U.S. revenue grew 29% sequentially. The full-year outlook came down roughly 10% at the midpoint. The stock opened through its prior 52-week low of $1.11 and was still at $0.93 in afternoon trading, down about 16% — below a dollar for the first time in at least a year.

The Belgian medtech sells Genio, a hypoglossal nerve stimulation implant for obstructive sleep apnea that won FDA approval in August 2025. Its U.S. launch is the whole investment case, and Monday's release is the launch's report card: approximately €9.2 million in global net revenue, up 19% sequentially, with the U.S. contributing approximately €6.7 million, up 29% from the second quarter. "We delivered 29% sequential revenue growth in the U.S. in the third quarter," CEO Liam Kelly said, adding that the company was "disappointed to adjust our full year revenue guidance to €33 to €35 million" but "still pleased with the acceleration in growth."

Here is the arithmetic the press release leaves to the reader. Nyxoah booked €14.0 million in the first half and roughly €9.2 million in the third quarter — call it €23.2 million through nine months. The old guidance of €36–40 million therefore required a fourth quarter of €12.8–16.8 million: sequential growth of 39% to 83%. The new €33–35 million range implies €9.8–11.8 million, or 7% to 28% growth. In other words, the cut is not a verdict on the quarter just reported; it is an admission that the fourth-quarter bar was set somewhere the ramp was never going to reach. Kelly's framing — that the U.S. ramp "is more reflective of historical ramps for a new technology, as physicians and centers build experience with Genio" — reads as a correction of the guidance, not of the business.

The commercial indicators mostly support that reading. Nyxoah trained 80 new U.S. surgeons in the quarter for a total of 342, activated 53 new accounts for a total of 233, and says 447 patients were actively under prior authorization entering Q4 — a visible pipeline for a procedure that bills ahead of implantation. The clinical story is stronger still: the ACCCESS pivotal study in complete concentric collapse (CCC) patients met its co-primary efficacy and safety endpoints, with a 77.2% twelve-month AHI responder rate (p<0.001) and zero device- and procedure-related serious adverse events, and a PMA supplement is now in front of the FDA under Breakthrough Device Designation. CCC anatomy is excluded under the incumbent therapy's U.S. labeling, so an approval would hand Nyxoah a patient population its larger competitor cannot touch.

Then there is the other ledger. Cash, cash equivalents and financial assets stood at approximately €77.0 million on September 30, against €97.8 million on June 30 — a €20.8 million decline in a single quarter. Recall that Nyxoah raised roughly €76.0 million net in June by selling 55.2 million new shares at €1.48; one quarter consumed more than a quarter of that raise, and the stock now trades far below the June print. The June 30 balance sheet also carried €58.1 million of financial debt, including a €22.3 million convertible bond classified as current and €18.8 million drawn from the EIB. With roughly 100.1 million shares outstanding as of June 30, Monday's trade values the equity near $94 million — and Nasdaq's $1.00 minimum bid price rule starts mattering if the stock sustains these levels for 30 consecutive trading days.

The Filing

• Preliminary Q3 2026 global net revenue: ~€9.2M, +19% sequentially; U.S. ~€6.7M, +29% sequentially (unaudited)

• FY2026 guidance cut to €33–35M from €36–40M

• Cash, equivalents and financial assets: ~€77.0M at September 30, vs €97.8M at June 30

• 80 new U.S. surgeons trained (342 total); 53 new accounts activated (233 total); 447 patients under prior authorization entering Q4

• ACCCESS pivotal in CCC: co-primary endpoints met; 77.2% 12-month AHI responder rate (p<0.001); zero device/procedure-related SAEs; PMA supplement submitted under Breakthrough Device Designation

The Context

• Q1→Q2→Q3 2026 global revenue: €6.3M → €7.7M → €9.2M; the old guide still required €12.8–16.8M in Q4

• Guidance of €36–40M was reaffirmed in the August second-quarter report; the cut came ten weeks later

• June 2026 raise: 55.2M shares at €1.48/€1.49, ~€76.0M net; ~100.1M shares outstanding at June 30; June 30 financial debt €58.1M, including a €22.3M current convertible bond and €18.8M EIB facility

• Stock: $0.93 in Monday afternoon trade (−16%), prior close $1.11, 52-week range $1.11–$6.00 entering the day, down ~80% year to date

Bull: The launch is working — 29% sequential U.S. growth, a trained-surgeon base that grew 31% in one quarter, and a 447-patient authorization pipeline. ACCCESS gives Genio pivotal-grade data in CCC patients the incumbent's label excludes; approval would create a competitor-free segment. The guidance cut repriced expectations, not demand.

Bear: A company that reaffirmed €36–40 million in August cut it in October — guidance credibility is spent. €20.8 million of liquidity left in one quarter against €77.0 million remaining; at that pace the June raise buys roughly a year, with a current convertible and an EIB facility ahead of shareholders. Sub-$1 stocks fund launches on punitive terms, and the Nasdaq bid-price clock may soon be running.

Investor Action: Watch Signal.

• Q4 global revenue against the implied €9.8–11.8M bar — the first test of the reset guide

• FDA action on the CCC PMA supplement, the only near-term event that changes the competitive map

• The full Q3 report: operating burn versus the €20.8M headline decline, the September 30 debt balance, and any ATM or financing disclosure — plus the tape itself, with 30 consecutive closes below $1.00 starting Nasdaq's deficiency clock

SCN editorial — independent commentary for information only, not investment advice.